



Embarc Benefit Protection

2022 Surplus Announcement

Embarc Benefit Protection® is Cigna Healthcare's first-to-market network solution developed to increase access and affordability for high-cost, potentially life-changing gene therapy drugs as they are approved by the FDA. Since its launch in July of 2020, the solution has grown to include more than six million customers. To further differentiate this solution, Embarc Benefit Protection offers clients the opportunity to share in better-than-anticipated experience in the event of a surplus across our entire book of business. The annual surplus settlement provides transparency and prevents the charge for Embarc Benefit Protection from becoming disproportionate to aggregate drug cost.

Surplus Details for 2022:

Embarc Benefit Protection was priced to include two existing gene therapy drugs (LUXTURNA® and ZOLGENSMA®) as well as the potential for additional gene therapies projected to achieve FDA approval. For 2022, two new drugs were FDA approved (ZYNTEGLO® and SKYSONA®) and added under Embarc Benefit Protection. Market conditions, including alternative therapies and delayed FDA approval of additional gene therapies, led to lower-than-anticipated annual drug cost across the Embarc Benefit Protection book of business.

As a result, we are pleased to announce a book-of-business surplus of \$0.59 per member per month (PMPM). Annual drug costs across the Embarc Benefit Protection book of business for 2022 equaled \$0.06 PMPM. Cigna will retain 35% of the total \$0.99 PMPM charge for administrative costs of the network solution.

Timing for Surplus Allocation:

The 2022 surplus of \$0.59 PMPM will be returned on a pro rata basis directly to clients by March 31, 2023.

Looking Ahead for 2023:

Based on the information available today, we believe the FDA will approve a number of new gene therapies in 2023. Our goal is to provide our clients and customers access to these life-changing new gene therapies as they achieve FDA approval while continuing to maintain the predictable and affordable price of \$0.99 PMPM.*

* We reserve the right to change the PMPM charge for the Embarc Benefit Protection network solution as needed based on the inclusion of new therapies, price variations by manufacturers, or fluctuations in utilization rates. Price changes will be communicated in writing at least 30 days in advance.

LUXTURNA is the registered trademark of Spark Therapeutics, Inc. ZOLGENSMA is the registered trademark of Novartis, Inc. ZYNTEGLO and SKYSONA are both registered trademarks of bluebird bio, Inc.

Product availability may vary by location and plan type and is subject to change. All group health insurance policies have exclusions and limitations. For costs and details of coverage, contact a Cigna Healthcare representative.

Cigna Healthcare products and services are provided exclusively by or through operating subsidiaries of The Cigna Group, including Cigna Health and Life Insurance Company (CHLIC), or their affiliates.

968946 03/23 © 2023 Cigna Healthcare. Some content provided under license.

